,16,17 Of note, despite limited clinical efficacy of EGFR-targeting CAR T cells in early clinical trials, these side effects, including skin rashes, have been observed as well,11,12 suggesting that an increased potency will inevitably result in more severe toxicities due to enhanced reactivity against EGFR-positive healthy tissues. This evidence concerns the gene EGFR and Skin rash.